Biotech Startup Raises $175 Million to Advance Alzheimer’s Antibody Therapy

Biotech startup raises $175 million to advance Alzheimer’s antibody therapy

With two approved Alzheimer’s antibody therapies already on the market, is there room for more such treatments designed to clear out the sticky amyloid plaques associated with the disease? Well, investors at Fairmount, Venrock, Wellington Management, and TCGX believe so. They and other firms have handed $175 million over to a new company, Korsana Biosciences, to develop an Alzheimer’s medicine.  Korsana launched Wednesday with plans to test a ne…

Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases

WALTHAM, Mass.--(BUSINESS WIRE)--Feb 18, 2026-